3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Cholangiocarcinoma
3
Liver Neoplasms
2
Biliary Tract Neoplasms
2
Acrocephalosyndactylia
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Bile Duct Neoplasms
1
Interventions
Oxaliplatin
290
Capecitabine
206
Fluorouracil
181
Cisplatin
168
Docetaxel
138
S 1 (combination)
132
Paclitaxel
121
Leucovorin
116
Irinotecan
106
pembrolizumab
103
Trastuzumab
71
apatinib
56
Nivolumab
56
sintilimab
45
Drug Therapy
43
Surgical Procedures, Operative
37
Radiotherapy
37
Bevacizumab
37
Ramucirumab
34
titanium silicide
31
Hyperthermic Intraperitoneal Chemotherapy
30
Epirubicin
30
Carboplatin
30
tislelizumab
28
Cyclophosphamide
27
XELOX
24
Tegafur
23
Folfox protocol
22
Albumin-Bound Paclitaxel
22
camrelizumab
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Stomach Neoplasms
×
derazantinib
×
Clear all
NCT04604132
2024-04-04
FIDES-03
Basilea Pharmaceutica
Phase 1/2
Terminated
47 enrolled
22 charts